Neurizon Therapeutics Ltd Sustainability Reports
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being advanced for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 529900O3S715CU3F0342
FIGI: BBG001SC5SW8
2 reports from 2022 to 2025
